Retatrutide (LY3437943) is the first triple-incretin receptor agonist simultaneously targeting GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR). CAS: 2381089-83-2 | MW: ~4,681 Da. Supplied as lyophilised peptide at ≥98% purity for preclinical metabolic research. The 20mg vial supports higher-dose range studies and larger animal model experiments.

Research Background

Retatrutide was developed by Eli Lilly as an advance beyond dual GIP/GLP-1 agonism (tirzepatide), adding glucagon receptor co-agonism. The rationale: GLP-1R provides glucose-dependent insulin secretion; GIPR adds complementary metabolic benefits including adipose effects; GCGR increases energy expenditure and hepatic glucose output – counterbalancing hypoglycaemia risk. Phase 2 clinical trials have generated significant research interest in this triple agonist compound class.

Mechanism of Action & Metabolic Research

• GLP-1R agonism: Glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, satiety signalling, beta-cell preservation effects
• GIPR agonism: Complementary insulin secretion, adipose tissue lipolysis modulation, central satiety effects independent of GLP-1R
• GCGR agonism: Hepatic glucose output regulation, thermogenesis, increased energy expenditure – additional caloric deficit mechanisms beyond appetite suppression

Storage & Handling

• Long-term storage: -20°C (lyophilised stable 18-24 months)
• Short-term storage: 2-8°C for up to 3 weeks after reconstitution
• Reconstitution: Sterile bacteriostatic water; dissolve gently
• Handling: Aliquot to avoid repeated freeze-thaw; standard peptide handling

Related Research Compounds

Dose-ranging companion: Retatrutide 10mg. Comparative dual agonist: Tirzepatide 20mg. HPG axis metabolic context: Kisspeptin 5mg.

For research use only. Not for human or animal consumption. Not a medicinal product.